ArticleFrontiers in oncology2025
Integration of single-cell and bulk RNA sequencing to identify unique tumor stem cells and construct novel prognostic markers for assessing ESCA prognosis and drug sensitivity.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer stem cells (CSCs) are crucial contributors to the development and progression of esophageal cancer (ESCA). This study utilized single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (RNA-seq) to identify gene signatures of CSCs in ESCA, aiming to construct a prognostic tumor stem cell marker signature (TSCMS) model. Methods: We analyzed scRNA-seq and RNA-seq data of ESCA. CytoTRACE was used to quantify the stemness of tumor-derived epithelial cell clusters. The TSCMS model was developed using Lasso-Cox regression, and its prognostic significance was evaluated via Kaplan-Meier survival analysis, Cox regression, and ROC curve analysis. Drug response predictions were conducted using the pRRophetic package. Functional studies of TSPO in ESCA cells included bioinformatics analysis, quantitative reverse transcription PCR (qRT-PCR), Western blotting, immunohistochemistry, and cell proliferation assays. Results: Distinct cell cluster stemness potentials were identified using CytoTRACE. The TSCMS model consists of 18 tumor stemness-related genes. High-risk patients showed reduced immune and ESTIMATE scores, along with elevated tumor purity. Notable differences in immune infiltration and chemotherapy sensitivity were observed between risk groups. TSPO was found to be positively correlated with RNA expression-based stemness scores in various tumors, including ESCA. Its expression was diminished in ESCA cell lines and clinical tumor tissues, with low expression correlating with poor prognosis. Overexpression of TSPO inhibits the proliferation of ESCA cells and the formation of tumor clones. In a mouse model of esophageal carcinoma Conclusion: This study underscores the prognostic significance of the TSCMS model in ESCA, elucidates the immune landscape and treatment response, and identifies TSPO as a potential therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.